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Antiarrhythmic agents may increase capture threshold, but
this is rarely of clinical significance. Flecainide acetate, a class
IC agent, is reported to have a significant effect on the myo-
cardial capture threshold. In this presentation, we report the
case of a 72-year-old male, with a previously implanted VVI
pacemaker due to sick sinus syndrome, who was treated with
flecainide acetate for paroxysmal atrial arrhythmia control.
During the fifteenth day of treatment, an abrupt rise in the
ventricular capture threshold with ventricular pacing failure
was noted. The capture threshold decreased two days after dis-
continuation of flecainide acetate.
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INTRODUCTION
Various pharmacologic agents are known to
adversely affect the amplitude and duration of
action potentials in the myocardium. Rarely, in
patients with implanted permanent pacemakers,
pacemaker capture thresholds may be altered by
administration of antiarrhythmic agents. Flecai-
nide acetate, a class IC antiarrhythmic agent, has
been found to increase the capture threshold by
greater than 200%.
1-4
The combination of its
marked depressant effect on the rate of rise of the
action potential, and its relatively small effect on
the duration of the action potential, may have a
significant effect on myocardial capture thresh-
old.5
We herein report a case of a permanent pace-
maker capture failure with an abrupt rise of the
capture threshold due to flecainide acetate treat-
ment. The threshold was decreased only after
several days of flecainide acetate discontinuation.
CASE REPORT
A 72-year-old male with a medical history of
hypertension, diabetes mellitus, and chronic renal
failure on scheduled hemodialysis, was referred to
our cardiology division for paroxysmal episodes
of dyspnea and palpitations. The patient was sub-
sequently diagnosed with paroxysmal atrial flutter
and was advised to have sinus rhythm conversion
because of distressing symptom during hemodi-
alysis.
One year ago, the patient had a permanent
pacemaker (Vitatron Jade 3 SSI model, Medtronic,
Minneapolis, MN, USA) implanted due to sick
sinus syndrome. Initially, the acute capture
threshold was 0.3 V pulse amplitude and 0.4 ms
pulse duration. Thus, the pacemaker was pro-
grammed in the VVI mode with pacing amplitude
of 3.8 V and 0.4 ms pulse duration; it had func-
tioned well until recently.
We treated his atrial flutter with daily admini-
stration of oral flecainide acetate (200 mg), and the
patient's rhythm converted to sinus within three
days. He was discharged, free of symptoms, with
a reduced maintenance dose of daily flecainide
acetate (100 mg), in order to maintain sinus
rhythm.
Fifteen days after the flecainide acetate had
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been started, he was rehospitalized, via the emer-
gency department, due to the development of
severe dizziness and episodes of near syncope.
The ECG at the time of re-admission revealed
complete pacemaker capture failure with a wide
QRS idioventricular rhythm of 43/min (Fig. 1).
The pacemaker was immediately evaluated, and
the ventricular capture threshold was found to be
elevated at 5 V at 0.8 ms. There was no evidence
of pacemaker lead tip displacement or electrolyte
imbalance.
Flecainide acetate was suspected to be the cause
of the elevated capture threshold. Therefore, it
was immediately stopped, and the capture thresh-
old was adjusted to a maximum level over 5 V at
0.8 ms pulse duration, with a good capture of
pacemaker beat (Fig. 2). After discontinuation of
flecainide acetate, the capture threshold decreased
rapidly. Two days after drug cessation, pacing
threshold improved to 2.4 V at 0.8 ms. The patient
was discharged with instruction to follow-up at
the outpatient clinic.
DISCUSSION
The myocardial threshold to electrical stimula-
tion (capture threshold) is sensitive to a variety of
physiologic, pathologic, and pharmacologic changes
that affect the heart. Flecainide acetate, a class IC
agent, may especially have a profound effect on
ventricular capture threshold because of its
marked depressant effect on the rate of rise of the
action potential and relatively small effect on
action potential duration.5 Previous reports have
shown that flecainide acetate may cause a greater
than 200% or 117% increase in pacing threshold
following oral or intravenous administration,
respectively.1,2 In our patient, who initially
showed an adequate capture threshold and a
pacemaker programmed to its maximum output,
administration of fifteen days of flecainide acetate
led to an abrupt increase in capture threshold
from 0.4 V to 5.0 V with subsequent development
of pacemaker capture failure. There have been few
prior reports which have documented flecainide
acetate effect on the moment to moment increase
and regression of the ventricular capture
threshold. Perez et al.,
4
reported these moment to
moment changes in capture threshold by
analyzing previous records of pacing thresholds.
They demonstrated that the threshold increase
started immediately following the first dose of
medication. The threshold continued to increase
even after a stable serum level should have been
achieved (by two and half days following
initiation of therapy). The temporal course of the
ventricular capture threshold provides compelling
evidence supporting an adverse effect of fle-
cainide acetate on the ventricular capture thresh-
old. In our experience, we noted that our patient's
capture threshold decreased from 5 V to 2.4 V
within two days of flecainide cessation.
In retrospect, especially in such a patient with
expected unstable pacing threshold, we should
have considered the use of a newly developed
Fig. 1. The ECG tracing on rehospitali-
zation shows capture failure with wide
QRS idioventricular rhythm of 43/min.
The second, fourth, and sixth QRS com-
plexes were sensed and made each
pacing blip (initial settled ventricular
rate was 60/min).
Fig. 2. Well captured beat after resetting
of pacemaker capture threshold to 5 V
at 0.8 ms pulse duration and discon-
tinuation of flecainide.
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automatic threshold tracking pacing system. This
system verifies ventricular capture beat-by-beat by
recognizing the evoked response (ER) following
each pacemaker stimulus.7
In addition, it is acknowledged that pacemaker
output must be adjusted with a 100% voltage
safety margin above the pacing threshold, to
avoid ineffective pacing. Schuchert et al.8 reported
that low setting of the ventricular pacing output,
in pacemaker dependent patients (especially
100%), is not safe in some cases. They suggested
that, in patients implanted with low ventricular
output programmed pacemakers, an intermittent
increment of the pacing threshold should always
be ruled out when they have symptoms of inef-
fective pacing.
Oral flecainide is well absorbed, with peak
plasma concentrations occurring two to four
hours after dosing. The average elimination half-
life is twenty hours after repeated doses. In
healthy subjects, approximately 70% of flecainide
is metabolized in the liver, and 30% is excreted
unchanged in the urine.6 Therefore, dosage should
be adjusted in patients with poor renal function.
In this case, a number of factors, such as old age
and poor renal function, may have enhanced the
drug effect.
Since the great majority of implanted perma-
nent pacemaker patients are elderly, and many
have similar degrees of cardiac and renal insuf-
ficiency,5 we should always consider appropriate
dose adjustments of antiarrhythmic drugs. The
clinical implication of this case is the fact that
flecainide acetate and, possibly, other class IC
antiarrhythmic agents, must be used with great
caution in patients with implanted pacemakers,
particularly if they have impaired renal function.
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